Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Posaconazole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Posaconazole. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-000161-36 Sponsor Protocol Number: P05267(MK-5592-055) Start Date*: 2013-07-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.,
    Full Title: Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267)
    Medical condition: Chronic Chagas Disease
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10066500 Chagas disease recurrent LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003940-38 Sponsor Protocol Number: POPK-1501 Start Date*: 2016-03-02
    Sponsor Name:Fundación Investigación Biomédica Puerta de Hierro
    Full Title: Plasma level pharmacokinetics study of posaconazole with the sequential use of two oral formulations (oral suspension and solid tablets) in haematology patients with a high risk of invasive mycoses.
    Medical condition: Invasive Mycoses
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003140-68 Sponsor Protocol Number: MK5592-105-00 Start Date*: 2012-10-29
    Sponsor Name:MSD
    Full Title: A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients
    Medical condition: Invasive fungal infection (IFI) in lung transplant patients with and without cystic fibrosis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10049085 Antifungal prophylaxis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002755-16 Sponsor Protocol Number: 23 Start Date*: 2007-11-07
    Sponsor Name:University Hospital Heidelberg
    Full Title: Pharmakokinetik von Posaconazol verabreicht über Magensonde - POLICE-Studie (POsaconazoLe via gastrIC tubE)
    Medical condition: All subjects are patients of a SICU. Apache Score > 30. Infection treatment or prophylaxis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004511-31 Sponsor Protocol Number: cASPerCF_2007_OPBG_2019 Start Date*: Information not available in EudraCT
    Sponsor Name:Bambino Gesù Children's Hospital
    Full Title: Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.
    Medical condition: Cystic Fibrosis and Aspergillus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Prematurely Ended) GR (Prematurely Ended) FR (Prematurely Ended) NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002579-16 Sponsor Protocol Number: CF001 Start Date*: 2018-08-26
    Sponsor Name:Karolinska University Hospital, Stockholm CF center
    Full Title: Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus sp...
    Medical condition: Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane con...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10074549 Cystic fibrosis respiratory infection suppression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003938-14 Sponsor Protocol Number: MK-5592-069(P06200) Start Date*: 2013-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)
    Medical condition: Invasive aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10003488 Aspergillosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) LT (Prematurely Ended) PT (Completed) GB (Completed) EE (Completed) IT (Completed) PL (Completed) GR (Completed) FR (Completed) HU (Completed) CZ (Completed) HR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-001182-87 Sponsor Protocol Number: UMCN-AKF16.01 Start Date*: 2017-01-10
    Sponsor Name:Radboud University Medical Centre
    Full Title: Pharmacokinetics of posaconazole (Noxafil(R)) as prophylaxis for invasive fungal disease
    Medical condition: prophylaxis for patients at high risk for invasive fungal diseases
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001585-15 Sponsor Protocol Number: 2018-01671 Start Date*: 2020-01-30
    Sponsor Name:Centre Hospitalier Universitaire Vaudois
    Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia
    Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-007712-14 Sponsor Protocol Number: 1120081 Start Date*: 2009-01-17
    Sponsor Name:Erasme Hospital
    Full Title: Monitoring of serum concentrations of posaconazole given as prophylaxis or therapy.
    Medical condition: fungal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017533 Fungal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020832-20 Sponsor Protocol Number: P06356 Start Date*: 2010-08-13
    Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation - for Global trials
    Full Title: An Evaluation of the Safety and Pharmacokinetics of Posaconazole (POS, SCH 56592) IV Solution via Peripheral Administration in Healthy Volunteers (P06356)
    Medical condition: This study is going to be conducted in heathy volunteers.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020953-14 Sponsor Protocol Number: PosaBupreversion1.0 Start Date*: 2010-08-12
    Sponsor Name:Derartment of Anaesthesiology and Intensive Care, Turku University Hospital
    Full Title: Effects of posaconazole and voriconazole on the pharmacokinetics and pharmacodynamics of sublingual buprenorphine: A three-phase double-blind cross-over study in healthy subjects.
    Medical condition: - healty volunteer subjects - The study is aimed to examine the possible interactions of low-dose sublingual buprenorphine with posaconazole and voriconazole.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004518-28 Sponsor Protocol Number: UMCN-AKF 08.01 Start Date*: 2008-11-19
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Investigation of posaconazole prophylaxis in children with chronic granulomatous disease (CGD): pharmacokinetics and tolerability (iPOD)
    Medical condition: Children with chronic granulomatous disease (CGD).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008906 Chronic granulomatous disease LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002271-97 Sponsor Protocol Number: F901318C21 Start Date*: 2017-04-07
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing che...
    Medical condition: Invasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002267-10 Sponsor Protocol Number: MK-5592-104 Start Date*: 2019-12-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Open-Label, Non-Comparative Clinical Trial to Study the Safety and Efficacy of Posaconazole (POS, MK-5592) in Pediatric Participants Aged 2 to <18 Years With Invasive Aspergillosis
    Medical condition: Invasive aspergillosis (IA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10003488 Aspergillosis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) Outside EU/EEA GR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003842-34 Sponsor Protocol Number: MK-5592-127 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul...
    Medical condition: Invasive Fungal Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003270-14 Sponsor Protocol Number: POSA-FLU Start Date*: 2017-11-06
    Sponsor Name:UZ Leuven
    Full Title: A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of Posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patients
    Medical condition: invasive aspergillosis in critically ill patients with influenza pneumonia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002807-10 Sponsor Protocol Number: 5592-097 Start Date*: 2015-09-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects with Neutropenia
    Medical condition: Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10017534 Fungal infection NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) BE (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004645-15 Sponsor Protocol Number: P03579 Start Date*: 2008-03-14
    Sponsor Name:Schering Plough Research Institute
    Full Title: Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia
    Medical condition: treatment and prophylaxis of invasive fungal infections; oropharyngeal candidiasis (OPC) and refractory OPC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050346 Oropharyngeal candidiasis LLT
    9.1 10017528 Fungal infectious disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003717-33 Sponsor Protocol Number: P02095 Start Date*: 2005-09-13
    Sponsor Name:SCHERING-PLOUGH
    Full Title: Open-Label, limited access protocol of Posaconazole in invasive fungal infections.
    Medical condition: Profilaxys of invasive mycotic infections in high risk neutropenic patients.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10017533 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 23:49:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA